The stock's fall snapped a two-day winning streak.
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...
Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...
Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
Hosted on MSN7d
UNAIDS Calls On Leaders At Davos To Commit To Rapid Global Access To Revolutionary New Long-Acting HIV MedicinesUNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback